Abstract
Background
High‐dose statin therapy may be underutilized in aged patients due to doubts about efficacy and safety.
Hypothesis
To investigate outcomes and safety in patients aged 65–78 years compared with patients aged < 65 years in the ALLIANCE study.
Methods
A total of 2,442 stable coronary heart disease (CHD) patients with dyslipidemia were randomized to either aggressive treatment (low‐density lipoprotein cholesterol titration goal of < 80 mg/dL or maximum 80 mg/d of atorvastatin) or usual care (continuation of baseline lipid‐lowering therapy, with changes and laboratory analyses directed by treating physicians).
Results
A total of 1,001 patients aged 65–78 years were followed for a median period of 53.9 mo. Older, aggressively treated atorvastatin patients experienced a 27% relative risk reduction for the primary composite endpoint of adverse cardiovascular outcomes (hazard ratio [HR]: 0.73; 95% confidence intervals [CI]: 0.57–0.94; p = 0.016). In addition, significant risk reductions were observed for nonfatal myocardial infarction (MI; HR: 0.43; 95% CI: 0.23–0.79; p = 0.006), cardiac revascularization (HR: 0.67; 95% CI: 0.48–0.93; p = 0.017), and the combined endpoint of cardiac death and nonfatal MI (HR: 0.48; 95% CI: 0.32–0.72; p = 0.001). The rate of significant liver transaminase elevations in atorvastatin patients was low and not age related. There were no cases of rhabdomyolysis. The rate of study discontinuations due to serious adverse events was higher in patients aged 65–78 years than in those younger than 65 years, but was similar between the treatment groups.
Conclusions
Our data support the efficacy and safety of aggressive lipid management with atorvastatin in older CHD patients. Copyright © 2009 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (1.1 MB).
References
- 1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, et al.: Heart disease and stroke statistics‐2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85–e151. [DOI] [PubMed] [Google Scholar]
- 2. Muntner P, Garrett E, Klag MJ, Coresh J: Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age. Stroke 2002; 33: 1209–1213. [DOI] [PubMed] [Google Scholar]
- 3. Kochanek KD, Murphy SL, Anderson RN, Scott C: Deaths: Final data for 2002. Natl Vital Stat Rep 2004; 53: 1–115. [PubMed] [Google Scholar]
- 4. Hunt D, Young P, Simes J, Hague W, Mann S, et al.: Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001; 134: 931–940. [DOI] [PubMed] [Google Scholar]
- 5. Miettinen TA, Pyorala K, Olsson AG, Musliner TA, Cook TJ, et al.: Cholesterol‐lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96: 4211–4218. [DOI] [PubMed] [Google Scholar]
- 6. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002; 360: 1623–1630. [DOI] [PubMed] [Google Scholar]
- 7. Deedwania P, Stone PH, Bairey Merz CN, Cosin‐Aguilar J, Koylan N, et al.: Effects of intensive versus moderate lipid‐lowering therapy on myocardial ischemia in older patients with coronary heart disease: Results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115: 700–707. [DOI] [PubMed] [Google Scholar]
- 8. Allen Maycock CA, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, et al.: Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol 2002; 40: 1777–1785. [DOI] [PubMed] [Google Scholar]
- 9. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK: Outcomes of using high‐ or low‐dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007; 147: 1–9. [DOI] [PubMed] [Google Scholar]
- 10. Koren MJ, Hunninghake DB: Clinical outcomes in managed‐care patients with coronary heart disease treated aggressively in lipid‐lowering disease management clinics: The ALLIANCE study. J Am Coll Cardiol 2004; 44: 1772–1779. [DOI] [PubMed] [Google Scholar]
- 11. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–239. [DOI] [PubMed] [Google Scholar]
- 12. Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L‐TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid‐lowering therapy and achieving low‐density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459–467. [DOI] [PubMed] [Google Scholar]
- 13. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower‐than‐average cholesterol concentrations, in the Anglo‐Scandinavian Cardiac Outcomes Trial‐Lipid Lowering Arm (ASCOT‐LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149–1158. [DOI] [PubMed] [Google Scholar]
- 14. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo‐controlled trial. Lancet 2004; 364: 685–696. [DOI] [PubMed] [Google Scholar]
- 15. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504. [DOI] [PubMed] [Google Scholar]